Recent studies have suggested that novel weight-loss drugs targeting glucagon-like peptide-1 (GLP-1) may also improve HFpEF symptoms, but their effect on important outcomes like hospitalization and death has not been evaluated in large populations
The glucagon-like peptide-1 (GLP-1) receptor agonist drug class, used to manage type 2 diabetes, is also proving to be highly effective for the treatment of obesity and has the potential to meet this growing need
Like any prescription medication, they are not appropriate for everyone, which is why a thorough medical evaluation before starting is essential
We ensure all our products are third-party tested and NSF for Sport certified because we know that trust is the foundation of any wellness routine
2022 Dec 15;387(24):2245-2257
Russias Arms Buyers Rejoice Over Trumps Deal With Turkey Derek Grossman , a professor of political science and international relations at the University of Southern California